胃痞消治疗慢性萎缩性胃炎的临床研究

【目的】通过临床试验研究,探讨胃痞消治疗慢性萎缩性胃炎的临床疗效。【方法】将符合纳入标准的58例慢性萎缩性胃炎脾胃虚弱证患者随机分为胃痞消组和胃复春组,每组各29例。胃痞消组采用口服中药汤剂胃痞消治疗,胃复春组采用口服中成药胃复春片治疗,治疗时间为12周。观察2组患者治疗前后症状积分和病理积分的变化情况,并评价其临床疗效。【结果】(1)症状积分方面:治疗后,2组患者主症和次症的症状积分均较治疗前明显下降(P0.05),且胃痞消组的下降作用均明显优于胃复春组,差异均有统计学意义(P0.05)。(2)临床疗效方面:胃痞消组和胃复春组的总有效率分别为96.55%、93.10%,胃痞消组的疗效优于胃复春组,差异有统计学意义(P0.05)。(3)胃黏膜病理学改变方面:治疗后,2组患者胃黏膜萎缩、肠上皮化生积分均较治疗前下降(P0.05);胃痞消组治疗后不典型增生积分下降(P0.05),而胃复春组治疗后不典型增生积分下降不明显(P0.05);组间比较,胃痞消组在降低胃黏膜萎缩积分方面优于胃复春组(P0.05)。【结论】胃痞消对脾胃虚弱型慢性萎缩性胃炎有良好的疗效,能改善慢性萎缩性胃炎的症状和胃黏膜萎缩、肠上皮化生的病理改变。

Clinical Efficacy of Weipixiao in Treating Chronic Atrophic Gastritis

Objective To investigate the clinical curative effect of Weipixiao for the treatment of chronic atrophic gastritis (CAG). Methods A total of 58 CAG patients with spleen-stomach deficiency syndrome was evenly randomized into Weipixiao group and Weifuchun group. Weipixiao group was treated with Weipixiao decoction orally,and Weifuchun group was treated with Weifuchun tablets orally. The treatment time covered 12 weeks. The scores of symptoms and pathology of CAG patients were graded before and after treatment. The clinical efficacy was evaluated with the symptom scores and pathological scores. Results (1)The scores of primary symptoms and secondary symptoms in the two groups were obviously decreased after treatment (P < 0.05 compared with those before treatment),and the decrease in Weipixiao group was superior to that in Weifuchun group(P< 0.05).(2) The total effective rate for clinical efficacy in Weipixiao group and Weifuchun group was 96.55%, 93.10%respectively, the difference being significant (P < 0.05). (3)After treatment, the scores of gastric mucosal atrophy and intestinal metaplasia in the two groups were obviously decreased after treatment (P < 0.05 compared with those before treatment),and the scores of gastric mucosal atypical hyperplasia were decreased obviously in Weipixiao group(P<0.05) but not obviously in Weifuchun group(P>0.05). The inter-group comparison results showed that Weipixiao group had better effect on decreasing gastric mucosal atrophy scores than Weifuchun group(P<0.05). Conclusion Weipixiao has good curative effect for the treatment of CAG patients with spleen-stomach deficiency syndrome through relieving the symptoms and improving the pathological changes of gastric mucosal atrophy and intestinal metaplasia.